Compare
Nuvectis Pharma, Inc. vs Valion Bio, Inc. vs Equillium, Inc. vs Tvardi Therapeutics, Inc.
| Latest fiscal year | Nuvectis Pharma, Inc. NVCT | Valion Bio, Inc. VBIO | Equillium, Inc. EQ | Tvardi Therapeutics, Inc. TVRD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | n/a |
| Revenue growth (YoY) | n/a | n/a | n/a | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/a |
| Net margin | n/a | n/a | n/a | n/a |
| Net income | -$26.44M | -$8.88M | -$22.40M | -$18.21M |
| EPS (Diluted) | -$1.32 | n/a | -$0.39 | -$3.26 |
| Operating cash flow | -$16.01M | -$7.00M | -$22.75M | -$23.50M |
| Free cash flow | n/a | -$7.04M | -$22.79M | n/a |
| Cash & equivalents | $31.63M | $12.64M | $30.28M | $20.73M |
| Total assets | $31.71M | $31.61M | $31.89M | $32.07M |
| Total liabilities | $13.30M | $7.44M | $3.29M | $11.13M |
| Shareholders' equity | $18.41M | $16.80M | $28.60M | $20.95M |
| Return on year-end equity | -143.6% | -52.9% | -78.3% | -87.0% |
| Shares outstanding | 25.68M | 2.53M | 61.46M | 9.38M |
Revenue, most recent five fiscal years
| Fiscal year | Nuvectis Pharma, Inc. | Valion Bio, Inc. | Equillium, Inc. | Tvardi Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $780.0K Ended 2024-12-31 | $41.09M Ended 2024-12-31 | $7.14M Ended 2024-12-31 |
| 1 year earlier | n/a | $1.18M Ended 2023-12-31 | $36.08M Ended 2023-12-31 | $20.97M Ended 2023-12-31 |
| 2 years earlier | n/a | $1.84M Ended 2022-12-31 | $15.76M Ended 2022-12-31 | $41.87M Ended 2022-12-31 |
| 3 years earlier | n/a | $1.26M Ended 2021-12-31 | n/a | $23.03M Ended 2021-12-31 |
| 4 years earlier | n/a | n/a | n/a | $135.08M Ended 2020-12-31 |